GlassScriptPhysician profile
Elaine Beed
NPI 1326143777
$11,322.06
in general payments reported to CMS, 2019-2025
27 companies · $395 in 2025
The $395 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $259 · 2021: $4,733 · 2022: $2,288 · 2023: $950 · 2024: $1,727 · 2025: $395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,405 · Consulting Fee: $1,397 · Education: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,405.39 |
| Consulting Fee | $1,396.75 |
| Education | $269.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $3,565.00 | 2021 | |
| G1 Therapeutics, INC. | $1,500.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,119.25 | 2024 | |
| Novartis Pharmaceuticals Corporation | $940.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $705.31 | 2019-2024 | Imfinzi, Tagrisso |
| Daiichi Sankyo INC. | $559.76 | 2022 | |
| Merck Sharp & Dohme LLC | $382.33 | 2019-2023 | Keytruda |
| Incyte Corporation | $338.57 | 2023-2025 | Pemazyre, Monjuvi |
| Abbvie INC. | $338.01 | 2019-2025 | |
| Seagen INC. | $269.93 | 2021-2023 | |
| Celgene Corporation | $151.62 | 2019-2020 | |
| Pfizer INC. | $134.58 | 2019 | |
| Alexion Pharmaceuticals, INC. | $129.02 | 2024 | |
| Agios Pharmaceuticals, INC. | $124.98 | 2024 | Pyrukynd |
| Amgen INC. | $123.17 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $115.66 | 2021 | |
| Exelixis INC. | $112.44 | 2019 | |
| Astellas Pharma US INC | $109.37 | 2019 | |
| Eisai INC. | $108.44 | 2025 | |
| Tempus Ai, INC | $106.31 | 2024 | |
| Lilly USA, LLC | $100.36 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $77.51 | 2022 | |
| Glaxosmithkline, LLC. | $75.58 | 2020 | |
| Janssen Pharmaceuticals, INC | $46.64 | 2020 | |
| Caris Mpi, INC. | $46.37 | 2025 | Mi Cancer Seek |
| Takeda Pharmaceuticals U.S.A., INC. | $29.93 | 2022 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elaine Beed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.